Registry update — unassessed
A Phase II Randomized Placebo-Controlled Study of Fisetin and Exercise to Prevent Frailty in Breast Cancer Survivors
Trial registry update: RECRUITING. No results reported in the supplied registry record.
RCTRoutine significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Jul 30, 2026 · Discovered: Sep 15, 2026 · Assessed: — · Historical research backfill
What it does not prove
- No sample size or effect size reported, preventing assessment of statistical power or magnitude of any observed benefit
- Phase II design means this is exploratory work; efficacy and safety endpoints are not specified in the abstract, so actual outcomes remain unknown
- The mechanism (senescent cell elimination) is stated as rationale but no biomarker data showing actual senescent cell reduction is mentioned
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Breast cancer survivors
- Primary outcome
- Prevention of frailty in breast cancer survivors
- Effect size
- —
- Significance
- Not reported
- Journal
- Jonsson Comprehensive Cancer Center
- Published
- Jul 30, 2026
Sources
Primary source
- Jonsson Comprehensive Cancer Center ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
This phase II trial tests how well fisetin and exercise works in preventing frailty in breast cancer survivors
Fisetin is a natural substance found in strawberries and other foods and is available as a nutritional supplement
Giving fisetin may eliminate senescent cells in patients with breast cancer undergoing physical activity
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.